In a notable development within the pharmaceutical industry, Teva Pharmaceuticals USA, Inc., a heavyweight in generic drug manufacturing, has concluded a settlement to the tune of $25 million. This settlement comes in response to accusations against the New Jersey-based company under the False Claims Act for their involvement in price-fixing and market allocation conspiracies for generic drugs. As reported by the Department of Justice, this civil settlement forms part of a broader $450 million resolution, tailored according to Teva's financial capacity, concluding allegations of both this and another improper kickback setup.
The allegations, as detailed by the U.S. Attorney's Office, point to a disconcerting collusion between May 1, 2013, and December 31, 2015. It was during this period that Teva is said to have engaged in illegal payment exchanges with other pharmaceutical entities concerning pravastatin, a popular cholesterol medication, and tobramycin, an antibiotic. Jacqueline C. Romero, U.S. Attorney, underlined the seriousness of such kickback arrangements, stating, “Kickback arrangements by pharmaceutical companies escalate the costs for critical drugs used by our citizens and federal health care programs.”
The ramifications of this illicit activity extend far beyond the confines of the pharmaceutical industry, casting shadows over the sanctity of federal health programs. Principal Deputy Assistant Attorney General Brian M. Boynton underscored the Department of Justice's commitment, declaring, “The Department is committed to pursuing all those who engage in kickback violations, including drug manufacturers, to ensure that these federal health care programs continue to serve the interests of taxpayers and program beneficiaries.”
Further to the civil settlement, Teva has previously conceded to a deferred prosecution agreement, shouldering a criminal penalty of $225 million that complements this latest civil settlement. The total of these resolved allegations paints a broader picture of governmental efforts to thwart healthcare fraud. Assisting in these efforts, Assistant U.S. Attorneys Landon Y. Jones III, Rebecca S. Melley, and Anthony D. Scicchitano, alongside Senior Trial Counsel Jennifer L. Cihon and Senior Litigation Counsel Laurie A. Oberembt, have been pivotal in getting to the bottom of such fraudulent behavior in the pharmaceutical sector.
